Determination Of the Effectiveness and Acid Neutralization Capacities (ANC) Of Some Commercial Antacid Tablets

References

[1] Abdu, K and Abbagana, M. (2015). ‘Evaluation of Neutralizing Capacity of different Commercial Brands of Antacid Tablets.’ Chemsearch Journal. 6(2):32-34.

[2] Abuhelwa, A.Y., Williams, D.B., Upton, R.N and Foster, D.J. (2017). Food, Gastrointestinal pH, and Models of Oral Drug Absorption. Eur J Pharm Biopharm. 112:234–48.

[3] Allen, L.V Jr., Popovich, N.G and Ansel, H.C. (2010). Ansel’s Pharmaceutical Dosage forms and Drug Delivery Systems, ninth edition. J Pharm Technol. 26(3):167–8.

[4] Bergström, C.A.S., Holm, R., Jørgensen, S.A., Andersson, S.B.E., Artursson, P and Beato, S. (2014). Early Pharmaceutical Profiling to Predict Oral Drug Absorption: Current Status and Unmet Needs. Eur J Pharm Sci. 57:173–99.

[5] Chandra, P., Kishore, K and Ghosh, A.K. (2015). Evaluation of Antisecretory, Gastroprotective and in Vitro Antacid Capacity of Fumaria Indica in Rats. Journal of Environmental Biology. 36(5): 1137-1142.

[6] Drake, D and Hollander, D. (2012). Annals of Internal Medicine, 94, 215-217.

[7] Ebenezer, O., Samuella, B.I and Ken, E. (2015). Canadian Open Pharmacy Journal, 2(1), 1-8.

[8] Farzaei, M.H., Mohammad, R.S., Zahra, A and Roja, R. (2013). Scientific Evaluation of Edible

[9] Jagadesh, K and Chidanda, K.N. (2015). Study of Acid Neutralizing Capacity of Various Antacid Formulations. Asian Journal of Pharmaceutical Technology and Innovation. 3(12):1-6.

[10] Johnson, D.A., Katz, P.O., Armstrong, D., Cohen, H., Delaney, B.C and Howden, C.W. (2017). The Safety of Appropriate use of Over-the-Counter Proton Pump Inhibitors: An Evidence-Based Review and Delphi Consensus. Drugs. 77(5):547–61.

[11] Kibwage, I.O., Machine,A., Hagos, B and Hoogmartens, J. (2011). East African Medical Journal, 72(3), 194-197.

[12] Kuzin, M., Schoretsanitis, G., Haen, E., Stegmann, B., Hiemke, C and Grunder, G. (2018). Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine. Clin Pharmacokinet. 57(6):729–37.

[13] Lee, S.J and Shin, J.G. (2014). The Pharmacogenomics of Cytochrome P450s: from Molecular to Clinical Application. In: Yamazaki H, editor. Fifty Years of Cytochrome P450 Research. Tokyo: Springer Japan; p. 345–70.

[14] Lee, J.S., Cho, J.Y., Song, H., Kim, E.H and Hahm, K.B. (2012). Revaprazan, A Novel Acid Pump Antagonist, Exerts Anti-Inflammatory Action against Helicobacter Pylori-Induced COX-2 Expression by Inactivating Akt Signaling. J Clin Biochem Nutr. 2012;51(2):77–83.

[15] Ogawa R and Echizen, H. (2010) Drug-Drug Interaction Profiles of Proton Pump Inhibitors. Clin Pharmacokinet. 49(8):509–33.

[16] Ogawa, R and Echizen H. (2011). Clinically Significant Drug Interactions with Antacids: An Update. Drugs. 71(14):1839–64.

[17] Pali-Scholl, I and Jensen–Jarolim, E. (2011). Antiacid Medication as a Risk Factor for Food Allergy. Allergy 66 (4): 469-77.

[18] Trevor, A.J, Katzung, B.G and Kruidering-Hall, M. (2015). Katzung and Trevor’s Pharmacology: Examination and Board Review. 11th ed. New York: McGraw-Hill; p. 35–40.

[19] Yang, X., Li, Y., Sun, Y., Zhang, M., Guo, C and Mirza, I.A. (2018). Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases. Dig Dis Sci. 63(2):302–11.

[20] Yoshida, T., Lai, T.C., Kwon, G.S and Sako, K. (2013). pH- and Ion-Sensitive Polymers for Drug Delivery. Expert Opin Drug Deliv. 10(11):1497–513.

[21] Zhang, L., Wu, F., Lee, S.C and Zhao, H. (2014). pH-dependent Drug–Drug Interactions for Weak Base Drugs: Potential Implications for New Drug Development. Clin Pharmacol Ther. 96(2):266–77.

[22] Zajac, P., Holbrook, A., Super, M.E and Vogt, M. (2013). An Overview: Current Clinical Guide Lines for the Evaluation, Diagnosis, Treatment and Management of dyspepsia. Osteopathic family physician 5 (2) 79-85.

[23] Zanger, U.M and Schwab, M. (2013). Cytochrome P450 Enzymes in Drug Metabolism: Regulation of Gene Expression, Enzyme Activities, and Impact of Genetic Variation. Pharmacol Ther. 138(1):103–41.

@article{1702876,
      author = {Ahmed Momoh Hassan},
      title = {Determination Of the Effectiveness and Acid Neutralization Capacities (ANC) Of Some Commercial Antacid Tablets},
      journal = {Iconic Research And Engineering Journals},
      year = {2021},
      volume = {5},
      number = {1},
      pages = {335-344},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1702876.pdf},
      abstract = {This study involves the evaluation of the effectiveness and acid neutralizing capacities (ANC) of five different commercial brands of antacid tablets. Antacids are substances commonly used by patients to obtain fast symptomatic relief from unpleasant feeling such as pain or burning sensation in the stomach or chest that is caused by difficulty in digesting food (dyspepsia or acid-indigestion). They are weak bases which neutralizes excess stomach acid and consequently raises the pH of the gastric contents and thus relief pains and alleviate symptoms of heartburn. The ultimate goal of antacid therapy is to reduce the concentration of acid in gastric juice to a pH of 4-5. The potency of the antacids depends mainly on their acid neutralization capacity (ANC) and this can vary from one brand to another. Five different but widely used commercial antacid tablets were selected for the purpose of this study. Each of the sample tablet was purchased, crushed, weighed and kept at room temperature before being analyzed using titrimetric method (back titration). The volume of the excess acid neutralized by NaOH for each of the antacid solution were Gelusil (Danacid) (9.50 ml), Gestid (16.80 ml), Omeprazole (Krishat) (15.30 ml), Emtrisil (13.00 ml), Gascol (12.50 ml) and Cimetidine (18.00 ml). The order of the acid neutralization capacity (ANC) of the antacid tablets from highest to lowest potency are Gelusil (Danacid) (40.5mEq), Gascol (37.5mEq), Emtrisil (37.0mEq), Omeprazole (34.7mEq), Gestid (33.2mEq), and Cimetidine (32.0mEq). Gelusil was the most active antacid with the highest value for antacid neutralizing capacity (40.5), hence, consumed the lowest volume of NaOH for the back titration process (9.50ml). Comparatively, cimetidine was the least active antacid with the lowest ANC valuen (32.0), hence, consumed the highest volume of NaOH (18.0ml).},
      keywords = {Antacids, Gastric juice, Acid neutralization capacity, Back titration.},
      month = {July},
  }